Notice for voretigene neparvevec (Novartis Pharmaceuticals Australia Pty Ltd)
Active ingredients
voretigene neparvevec
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Suspension for sub-retinal injection
Indication
Treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells.
Therapeutic area
Opthalmology